Therapeutic drug monitoring: is it cost-effective?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Expert review of pharmacoeconomics & outcomes research

• Publication date

  2002-12-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1586/14737167.2.6.619PMID 19807486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.

  2002cited by this paper
• Review: Therapeutic Drug Monitoring in Pediatrics

  2002cited by this paper
• Critical issues in therapeutic drug monitoring of antiretroviral drugs.

  2002cited by this paper
• Critical Issues in Therapeutic Drug Monitoring of Antiretroviral Drugs

  2002cited by this paper
• Pharmacogenetics

  2001cited by this paper
• Therapeutic Drug Monitoring

  2001cited by this paper
• A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy.

  2001cited by this paper
• Pharmacoeconomics of therapeutic drug monitoring in transplantation.

  2000cited by this paper
• Setting standards of practice in therapeutic drug monitoring and clinical toxicology: a North American view.

  2000cited by this paper
• Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.

  1999cited by this paper
• Clinical Pharmacokinetics in the 21st Century

  1998cited by this paper
• Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.

  1998cited by this paper
• Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies.

  1998cited by this paper
• Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics.

  1998cited by this paper
• Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring

  1998cited by this paper
• Therapeutic drug monitoring in special populations.

  1998cited by this paper
• Economic and outcome issues for therapeutic drug monitoring in medicine.

  1998cited by this paper
• The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin

  1997cited by this paper
• National survey of hospital-based pharmacokinetic services.

  1996cited by this paper
• Pharmaceutical services in a capitated geriatric care program.

  1996cited by this paper
• Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

  1996cited by this paper
• The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy

  1996cited by this paper
• How Important Is Therapeutic Drug Monitoring in the Prediction and Avoidance of Adverse Reactions?

  1995cited by this paper
• Cost Considerations in Therapeutic Drug Monitoring of Aminoglycosides

  1994cited by this paper
• Therapeutic Drug Monitoring and Patient Outcome

  1994cited by this paper
• Value, Limitations and Clinical Impact of Therapeutic Drug Monitoring in Adults

  1993cited by this paper
• Economic Aspects of Pharmacokinetic Services

  1993cited by this paper
• Use of Therapeutic Drug Monitoring in Pharmacoeconomics

  1993cited by this paper
• A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service.

  1992cited by this paper
• A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration

  1991cited by this paper
• Cost-effectiveness of therapeutic drug monitoring.

  1990cited by this paper
• Therapeutic Drug Monitoring Reduces Toxic Drug Reactions: A Meta‐Analysis

  1990cited by this paper
• Does Accepting Pharmacokinetic Recommendations Impact Hospitalization? A Cost‐Benefit Analysis

  1990cited by this paper
• Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost‐Benefit Analysis

  1990cited by this paper
• The cost-effectiveness of therapeutic drug monitoring.

  1990cited by this paper
• Serum drug level utilization: a literature analysis.

  1989cited by this paper
• The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

  1989cited by this paper
• Therapeutic drug monitoring

  1988cited by this paper
• Positive Impact of a Therapeutic Drug‐Monitoring Program on Total Aminoglycoside Dose and Cost of Hospitalization

  1987cited by this paper
• Cost-Effectiveness of Therapeutic Drug Monitoring

  1987cited by this paper
• Cost-benefit analysis of an aminoglycoside monitoring service.

  1986cited by this paper
• Therapeutic Drug Monitoring—the Need for Audit?

  1985cited by this paper
• Cost analysis of an aminoglycoside pharmacokinetic dosing program.

  1984cited by this paper
• Therapeutic Drug Monitoring

  1982cited by this paper
• Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis.

  1979cited by this paper

• Clinical awareness of therapeutic drug monitoring among medical students—A descriptive cross-sectional study

  2021cites this paper
• Pharmacoeconomic impact of methotrexate therapeutic monitoring at Benflis Touhami Batna’s University Hospital

  2018cites this paper
• Therapeutic Drug Monitoring for Immunosuppressive Agents

  2012cites this paper